🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The latest MBRRACE-UK Saving Lives, Improving Mothers’ Care report on women who died during or up to a year after pregnancy between 2020 and 2022 released today. Read more:buff.ly/2HR30eT @marianfknight @npeu_oxford @oxford_ndph

Our wonderful team at Denmark Hill site in support of World Thrombosis day! #WTDay24 #WorldThrombosisDay #MoveAgainstThrombosis

Camberwell at dusk

Chimeric antigen receptor T cell therapy might revolutionize the management and our understanding of autoimmune diseases An short educational thread🧵on current status and future directions

Science! Have you read the #PEERLESS trial comparing #thrombectomy (#LBMT) with #catheter-directed #thrombolysis (#CTD) for Intermediate-risk #pulmonary #embolism (#PE)? A critical read and analysis: 🧵1/5 ahajournals.org/doi/10.1161/CI…

MHRAgovuk Adeniyi Olagunju At The Equator ATTA Breastmilk Community 🇺🇬 British Journal of Clinical Pharmacology (BJCP) British Pharmacological Society DOLPHIN-3 Dr Natalie Shenker MBE The MPRINT Hub IMIConcePTION Carl Kirkpatrick Next, Jig Patel draws from his experience studying oral anticoagulants in breastfeeding mothers who did not require the drug for their own health. Strong community engagement approach, and surprising finding: large difference between rivaroxaban and apixiban #Pharmacology2024

MHRAgovuk Adeniyi Olagunju At The Equator ATTA Breastmilk Community 🇺🇬 British Journal of Clinical Pharmacology (BJCP) British Pharmacological Society DOLPHIN-3 Dr Natalie Shenker MBE The MPRINT Hub IMIConcePTION Carl Kirkpatrick Breastfeeding For Doctors Roopen Arya These studies can be challenging and we all need to learn from one another globally #Pharmacology2024 #AtTheEquatorUG pubmed.ncbi.nlm.nih.gov/39420408/

The 19th Annual Academy for Sickle Cell & Thalassaemia (ASCAT) in October focused on “Achieving Equitable Progress” in sickle cell & thalassaemia care. Highlights included: 🔬 Advancements in research & therapies 🤝 Tackling care inequalities 📈 Transformative projects More: slcn.nhs.uk/ascat/ #ASCAT2024

We’re excited to launch the new enhanced sickle cell community service, providing holistic, community-based care for people of all ages in south east London. Learn more: selondonics.org/new-enhanced-s…

We report 0.9% VTE within 90 days of hospital led acute ambulatory care attendance; similar to traditional medical inpatient care without thromprophylaxis. Further VTE research needed in this rapidly expanding area of medicine#VTE#SDEC Dan Lasserson sciencedirect.com/science/articl…

Today, we have launched MaTRON, our UK-wide project looking at management of intermediate and high risk PE in pregnancy. This data is desperately needed to help plan services and future studies. There's still time to get involved tinyurl.com/22b3ucwp Giulia Simini Professor Beverley Hunt OBE (also on BlueSky)

📢JTH is proud to announce the recipients of the 2025 JTH Editors’ Awards! These prestigious awards honor 6 early career investigators for their top articles in thrombosis & hemostasis. Join us in congratulating the winners🎉 & learn more: bit.ly/4lc2pFR

Day One at #NTW25 we welcome Professor Beverley Hunt OBE (also on BlueSky) & Roopen Arya to chair 'How can we improve VTE risk assessment tools & compliance across UK?' with Dr C Bagot, Dr G Benson, Christine Welburn & Ethel Oldfield. Register & join - have your comments & questions ready! tuk-edu.vfairs.com/en/

Ready to join NTW'25 today? Delighted to welcome Roopen Arya to our first session at 09:30 BST to discuss, 'Returning to everyday activity after a diagnosis of a blood clot' tuk-edu.vfairs.com

On our way to set up for Thrombosis UK's #VTEAwards! Today we celebrate achievement, innovation, service change and sheer hard work from individuals and teams to prevent, ensure prompt diagnosis & best management of #bloodclots. #safeguard improve #outcomes #recovery #lifesaving

The much used RoyalCollegeObsGyn Greentop guideline 37a is being revised. Here is a BJOG commentary from Laura A Magee and the guideline update committee. In the journal doi.org/10.1111/1471-0… and on video vimeo.com/1072760896

What can you expect in the first three months of recovery after a diagnosis of a blood clot? Check-out the video recording of Consultant Nurse Emma Gee discuss and answer FAQ on: 'Managing recovery in the first three months after a blood clot.' youtu.be/RdfILqvz88k?si…

Very innovative for #EHA2025 to run a session on Space Haematology. Roopen Arya very enlightening on the risks and potential treatment of VTE on a space station.

Wonderful to participate in first #Space #Haematology session at a Haematology conference thanks to #EHA2025 ! Pleasure to share the stage with Joseph ‘Sci’ Borg & Judith-Irina Buchheim covering rbc, wbc and clotting changes in space. European Hematology Association BSH - Haematology ASH

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025